RYBREVANT FASPROTM (amivantamab and hyaluronidase-lpuj) combination demonstrates a 77% overall response rate in the first treatment of patients with advanced head and neck cancer - the company announces - FT.com.

RYBREVANT FASPROTM (amivantamab and hyaluronidase-lpuj) combination demonstrates a 77% overall response rate in the first treatment of patients with advanced head and neck cancer - the company announces - FT.com.